CytRx Corporation announced that it has appointed Dr. Louis Ignarro succeeded Steven A. Kriegsman as Chairman of the Board of Directors on January 3, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3 USD | +8.70% | +6.66% | +130.77% |
Jun. 04 | LadRx Corporation and ImmunityBio, Inc. Mutually Agree to Terminate Aldoxorubicin License | CI |
May. 15 | LadRx Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
1st Jan change | Capi. | |
---|---|---|
+130.77% | 1.37M | |
+39.35% | 53.67B | |
+33.67% | 38.86B | |
-7.81% | 38.76B | |
-10.77% | 27.27B | |
+12.45% | 25.91B | |
-18.11% | 20.29B | |
+34.74% | 12.78B | |
+29.27% | 12.18B | |
-3.07% | 11.96B |
- Stock Market
- Equities
- LADX Stock
- News LadRx Corporation
- Cytrx Corporation Announces Changes to its Board